Home›Clinical trials›Colorado

GLP-1 clinical trials in Colorado: 18 recruiting now

By John Samaras, EditorRegistry checked September 4, 2026

18 GLP-1 clinical trials are recruiting at 21 sites in 4 cities across Colorado. Every site below is listed with its city and, where the sponsor publishes one, the number to call.

Every study recruiting in Colorado

  1. A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced

    Phase 3. Boehringer Ingelheim plans to enroll 1,800 participants.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis).

    2 sites in Colorado

    NCT06632444 on ClinicalTrials.gov. See whether you qualify.

  2. A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

    Phase 3. Boehringer Ingelheim plans to enroll 1,590 participants.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH), BMI 25+.

    2 sites in Colorado

    NCT06632457 on ClinicalTrials.gov. See whether you qualify.

  3. A study testing whether a GLP-1, GIP and glucagon medicine from Lilly, retatrutide, can help people reduce liver fat.

    A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

    Phase 3. Eli Lilly and Company plans to enroll 4,500 participants.

    Who can join. Adults 18+, have fatty liver disease (MASLD), BMI 25+.

    2 sites in Colorado

    • University of Colorado Anschutz Medical Campus, Aurora. 303-724-4651
    • South Denver Gastroenterology, Englewood

    NCT07165028 on ClinicalTrials.gov. See whether you qualify.

  1. A study testing whether a GLP-1 medicine, semaglutide, can help people with type 1 diabetes lower blood sugar.

    Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes

    Phase 3. University of Colorado, Denver plans to enroll 60 participants.

    Who can join. Adults 18 to 49, have type 1 diabetes, BMI 20+.

    1 site in Colorado

    • University of Colorado Anschutz Medical Campus, Aurora. 720-777-9500

    NCT05819138 on ClinicalTrials.gov. See whether you qualify.

  2. A study testing whether a GLP-1 medicine, semaglutide, can help people manage PCOS.

    Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome

    Phase 3. University of Colorado, Denver plans to enroll 80 participants.

    Who can join. Ages 12 to 35, women only, have polycystic ovary syndrome (PCOS), BMI 27+.

    1 site in Colorado

    • University of Colorado Anschutz/Children's Hospital Colorado Aurora, Aurora. 720-777-6984

    NCT05819853 on ClinicalTrials.gov. See whether you qualify.

  3. A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

    Phase 3. Eli Lilly and Company plans to enroll 125 participants.

    Who can join. Children and teens 6 to 17, have obesity.

    1 site in Colorado

    • Children's Hospital Colorado, Colorado Springs

    NCT06672549 on ClinicalTrials.gov. See whether you qualify.

  4. A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people ease joint pain.

    A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

    Phase 3. Eli Lilly and Company plans to enroll 800 participants.

    Who can join. Adults 18+, have osteoarthritis (joint pain), BMI 27+.

    1 site in Colorado

    NCT07153471 on ClinicalTrials.gov. See whether you qualify.

  5. A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people reduce bladder leaks.

    A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

    Phase 3. Eli Lilly and Company plans to enroll 1,000 participants.

    Who can join. Adults 18+, women only, have stress urinary incontinence (bladder leaks), BMI 27+.

    1 site in Colorado

    NCT07202884 on ClinicalTrials.gov. See whether you qualify.

  6. A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people improve blood flow in the legs.

    Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

    Phase 3. Eli Lilly and Company plans to enroll 1,205 participants.

    Who can join. Adults 18+, have peripheral artery disease (poor blood flow in the legs), BMI 23+.

    1 site in Colorado

    • Rocky Mountain Regional VA Medical Center, Aurora

    NCT07223593 on ClinicalTrials.gov. See whether you qualify.

  7. A study testing whether a study medicine from Novo Nordisk, cagrisema, can help people with type 2 diabetes lose weight.

    A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity

    Phase 3. Novo Nordisk A/S plans to enroll 2,500 participants.

    Who can join. Adults 18+, have obesity, BMI 35+.

    1 site in Colorado

    • University of Colorado Hospital, Aurora

    NCT07564414 on ClinicalTrials.gov. See whether you qualify.

The other 8 studies recruiting in Colorado

  1. A study testing whether a GLP-1 medicine, dulaglutide, can help people with cystic fibrosis lower blood sugar.

    GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance

    Phase 2. University of Pennsylvania plans to enroll 30 participants.

    Who can join. Adults 18+, have cystic fibrosis, BMI 19+.

    1 site in Colorado

    NCT04731272 on ClinicalTrials.gov. See whether you qualify.

  2. A study testing whether a GLP-1 medicine, semaglutide, can help people with diabetic kidney disease protect their kidneys.

    Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes

    Phase 2. University of Washington plans to enroll 60 participants.

    Who can join. Adults 18+, have diabetic kidney disease, BMI 20+.

    1 site in Colorado

    • University of Colorado Anschutz Medical Campus, Aurora. 720-689-4751

    NCT05822609 on ClinicalTrials.gov. See whether you qualify.

  3. A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with polycystic kidney disease protect their kidneys.

    Glucagon-Like Peptide-1 Receptor Agonist in ADPKD

    Phase 2. University of Colorado, Denver plans to enroll 126 participants.

    Who can join. Adults 18 to 65, have polycystic kidney disease, BMI 27+.

    1 site in Colorado

    • University of Colorado - Anschutz Medical Campus, Aurora. 303-724-4842

    NCT06582875 on ClinicalTrials.gov. See whether you qualify.

  4. A study testing whether an investigational medicine from Novo Nordisk, NNC0519-0130, can help people with chronic kidney disease protect their kidneys.

    A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living

    Phase 2. Novo Nordisk A/S plans to enroll 465 participants.

    Who can join. Adults 18+, have chronic kidney disease, BMI 27+.

    1 site in Colorado

    • Rocky Mount Reg VA Med-DN, Aurora

    NCT06717698 on ClinicalTrials.gov. See whether you qualify.

  5. A study of a GLP-1 medicine, semaglutide, in women going through menopause.

    Focusing on the Menopausal Transition to Improve Mid-Life Women's Health

    Phase 2. University of Colorado, Denver plans to enroll 200 participants.

    Who can join. Adults 45 to 55, women only, are going through menopause.

    1 site in Colorado

    • University of Colorado-School of Medicine, Aurora

    NCT06975111 on ClinicalTrials.gov. See whether you qualify.

  6. A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people quit smoking.

    Multi-Site Trial of Tirzepatide for Smoking Cessation

    Phase 2. University of Southern California plans to enroll 300 participants.

    Who can join. Adults 21 to 65, are trying to quit smoking, BMI 25+.

    1 site in Colorado

    • University of Colorado Anschutz Medical Campus, Aurora. 303-724-3196

    NCT07602699 on ClinicalTrials.gov. See whether you qualify.

  7. A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with obesity lose weight.

    Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents

    Phase 1. University of Colorado, Denver plans to enroll 40 participants.

    Who can join. Ages 12 to 24, have obesity.

    1 site in Colorado

    NCT06575738 on ClinicalTrials.gov. See whether you qualify.

  8. A study of a GLP-1 and GIP medicine, tirzepatide.

    Effects of GLP-1 RAs on Human Lactation Outcomes

    University of Colorado, Denver plans to enroll 18 participants.

    Who can join. Adults 18+, women only.

    1 site in Colorado

    • University of Colorado Anschutz School of Medicine, Aurora

    NCT07720414 on ClinicalTrials.gov. See whether you qualify.

Source: ClinicalTrials.gov, the federal registry, read September 4, 2026. Open a study's registry record before you call: it can close to new participants at any time. GLP Chart does not enroll anyone, is not paid for clinical-trial referrals and has no relationship with any sponsor or site on this page.

Screening for a study can take weeks. If you need the drug now, Strut Health is the cheapest cash route on the chart, from $149 a month. That price buys compounded semaglutide, a pharmacy-made version that is not FDA-approved and is not Wegovy, Ozempic, Zepbound or Mounjaro.

Check price →

Clinical trials by state

Every state with a GLP-1 study recruiting today. 48 of them.

John Samaras, editor of GLP Chart
Written and edited by John SamarasAbout this siteContact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.